were determined using PCR. The virulence determinants encoding the bio-component Panton-Valentine leukocidin (LukS/F-PV gene), exfoliative toxin (eta), alpha and delta hemolysin genes (hla and hld) were also ascertained by PCR. PFGE was used to predict the genetic relatedness of the MRSA isolates. Clusters were defined using the criterion of a difference of 6 bands, as described by Tenover et al 4 , and a similarity cut-off of 70.0%.
Results and discussion
The demographic data and resistance patterns of the isolates and MICs are summarized in Tables 1 and S1 All MRSA isolates were susceptible to daptomycin, vancomycin, linezolid, fusidic acid and tigecycline, ampillicin. The susceptibility Figure 1 . PFGE SmaI genotypic types generated from clinical MRSA isolates from private sector in KZN. Pretested Salmonella serotype Braenderup strain H9812 was used as the reference control strain. The R and S indicate resistance or susceptibility for ciprofloxacin, gentamicin, erythromycin, tetracycline and rifampicin respectively. The alphabets A-J shows the main pulsotype and subtype of each isolate. The numbers 1-15 indicates codes of the hospital centers where the MRSA isolates were collected.
patterns of the isolates in this study were comparable to studies conducted on MRSA in South Africa 5, 6 which were totally susceptible to daptomycin, vancomycin, linezolid, fusidic acid and tigecycline. The susceptibility of MRSA to these antibiotics observed in this study confirms their use as treatment options for infections in SA. The structural component of mecA encodes the penicillinbinding protein 2a (PBP2a) that establishes resistance to methicillin, other semisynthetic penicillinase-resistant beta-lactams that are frequently co-carried with genes conferring resistance to aminoglycosides, macrolide-lincosamide-streptogramin B [MLS B ] and spectinomycin. 8 All the isolated plasmids of the MRSA isolates contained the mecA and blaZ resistance genes, showing the correlation between MICs and the presence of genes encoding resistance against beta-lactams. The gentamicin resistance gene aac (6 0 )-aph (2 00 ) was identified in 25 (92.6%) of the isolates, which varied from the phenotypic resistance profile of 74.1%, indicating that gene carriage does not necessarily translate into the resistance phenotype. The ermC gene responsible for macrolide-lincosamidestreptogramins B [MLS B ] resistance was amplified in 48.2% (13/27) of the MRSA isolates, while it was not found in those that were susceptible to both erythromycin and clindamycin. The 23.5% (4/ 17) with phenotypic resistance to MLS B that did not contain the ermC gene indicates the occurrence of other resistance mechanism, ermA, ermB and msrA, which was not investigated in this study but have been previously reported. 9 This confirms that the incidence of MLS B phenotypes and genotypes vary according to country, patterns of infections and drug use. 9 Although there was high tetracycline resistance, the tetK gene was not detected, indicating that this may be due to different mechanisms and not mediated by active drug efflux, as tetK resistance has so far not been reported in clinical MRSA studies in South Africa. The prevalence of virulence factors in all isolated plasmids showed a similar trend, with the hla and hld being the most abundant genes, with frequencies of 96.3% (26/27) and 92.6% (25/27) respectively. Comparatively, this was similar to other studies conducted from Uganda 10 and United States, 11 with either hla being more frequent than the hld genes, or both showing 100% codominance. The prevalence rate of eta in our study was 0%, however, the prevalence of eta differed among studies, which could be associated with a variety of geographical and health conditions.
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LukS/F-PV was not detected in any of the 27 clinical MRSA isolates, which was comparable to a study conducted in South Africa on 320 clinical MRSA isolates with only one positive LuKS/F-PV gene being detected. 13 The PFGE profiles and the dendrogram of the MRSA isolates are shown in Figure 1 . PFGE analysis grouped the 27 isolates into 10 pulsotypes designated A-J, displaying 70.0% similarity, and correlating with their resistance profile and the genetic determinants tested in this study (Fig. 1) . Of note, 85.2% of the isolates were clustered into six major PFGE types: pulsotypes F (8/27 strains; 29.6%), G (5/27; 18.5%), C, I (3/27; 11.1%) and A, H (2/27; 7.4%). Pulse types B, D, E and J were each represented by single isolates. Although the sample size was too small to show a definite correlation, the assertion of similar circulating clones in the province was supported by our study, as the PFGE analysis revealed some form of association between pulsotypes and the centers of sample collection. Centers 1 and 10 were found to contain pulsotypes C and H, while identical pulsotypes F and G were spread across nine of the 15 centers, intimating the possibility of similar clones of MRSA within the health care centers in the province as predicted by Shittu et al 14 and
Moodley et al 13 in their study in KZN and SA respectively.
To the best of our knowledge this is the first study characterizing the plasmid-mediated resistance and virulence genes of clinical MRSA isolates in the private sector in Durban. The study provides a private sector perspective of antibotic resistance patterns and genetic relatedness of MRSA highlighting the need for implementing efficient and effective infection control programs.
